Overview

Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis

Status:
Recruiting

Trial end date:
2021-09-20

Target enrollment:
0

Participant gender:
All

Summary

This clinical trial serves to look at the effectiveness of SWRB for the treatment of mild to moderate Atopic Dermatitis in patients below the age of 18. Atopic Dermatitis (AD) is a common condition seen in dermatology, paediatric and primary care clinics in Malaysia. AD poses a significant biopsychosocial burden among sufferers and their families. Current management patterns of AD sufferers in South-east Asia mainly involve use of topical moisturizers and topical corticosteroids. Rice bran and products derived from it have been studied regarding their anti-oxidant, nutritional, cholesterol lowering and health promoting properties. However, there are very few studies that have focused on the benefits of SWRB when used topically. SWRB is cost-effective and easily available, while being an under-utilised product. The investigators wanted to study its effectiveness in controlling the signs and symptoms of Atopic Dermatitis when used as a cleanser and topical paste (emollient) as very little is known on this subject. The investigators wish to study participants below 18 years of age with mild and moderate Atopic Dermatitis. The participants will be followed up for four to six (4 - 6) weeks and the clinical features tabulated. This study does not involve any enteral or parenteral administration of SWRB. Neither does it involve any invasive procedures.

Phase:

Early Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

RCSI & UCD Malaysia Campus

Criteria

Inclusion Criteria:

- Patients below 18 years of age with mild and moderate Atopic Dermatitis

Exclusion Criteria:

1. Those over 18 years of age

2. Patients with other forms of dermatitis

3. Severe disease

4. Those already on other forms of topical therapies, which are likely to interfere with
outcomes